Jaguar Health, Inc. (JAGX) Stock Price & Analysis
Jaguar Health, Inc. (JAGX) rose 3.30% to USD 2.82 as of June 10, 2026 at 02:03 UTC, according to Nexqual real-time market data.
JAGX last closed at USD 2.73; the session ranged USD 2.58–2.82 on volume of 25,961 shares. Market capitalization is $2.04M, with a 52-week range of USD 2.53–137.2 (NCM). Source: Nexqual, June 10, 2026 at 02:03 UTC.
Key Statistics (as of June 10, 2026 at 02:03 UTC)
| Price | USD 2.82 |
|---|---|
| Change | ▲ 3.30% (up) |
| Previous Close | USD 2.73 |
| Open | USD 2.68 |
| Day Range | USD 2.58 – 2.82 |
| 52-Week Range | USD 2.53 – 137.2 |
| Volume | 25,961 shares |
| Market Cap | $2.04M |
| Exchange | NCM |
Technical Analysis (JAGX)
Nexqual's technical model rates JAGX "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:03 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 19.24 (oversold) |
| vs SMA50 | Below (USD 7.74) |
| MACD | -1.3 (negative) |
Analyst Ratings (JAGX)
Wall Street analysts rate JAGX "None" based on 1 analysts, with a mean price target of USD 262.5 (range USD 262.5–262.5), per Nexqual as of June 10, 2026 at 02:03 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 262.5 |
| High Target | USD 262.5 |
| Low Target | USD 262.5 |
Earnings (JAGX)
| Next Earnings Date | 2026-08-13 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -219.8 vs est -177.8 ▼ miss |
| 2025-06-30 | USD -259.26 vs est -249.55 ▼ miss |
| 2025-03-31 | USD -584.5 vs est -378.7 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:03 UTC.
Financials & Fundamentals (JAGX)
| Total Revenue | $29.57M |
|---|---|
| Revenue Growth (YoY) | +815.60% |
| Gross Margin | +85.06% |
| Operating Margin | +50.23% |
| Profit Margin | -115.40% |
| Current Ratio | 0.65 |
| Total Cash | $7.28M |
| Total Debt | $34.31M |
| Free Cash Flow | $-2.09M |
Source: Nexqual, June 10, 2026 at 02:03 UTC.
Financial Health Score (JAGX)
Nexqual rates Jaguar Health, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:03 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Mixed — $7M cash vs $34M debt |
| Cash Flow | Weak — FCF negative: -$2M, burning cash |
| Efficiency | Mixed — No data |
Ownership (JAGX)
| Insider Ownership | +5.76% |
|---|---|
| Institutional Ownership | +1.11% |
| Shares Outstanding | 722,024 |
| Float | 576,578 |
| Short % of Float | +9.29% |
Source: Nexqual, June 10, 2026 at 02:03 UTC.
Leadership (JAGX)
Jaguar Health, Inc. is led by Lisa A. Conte (age 66), Founder, CEO, President & Director, per Nexqual as of June 10, 2026 at 02:03 UTC.
| Founder, CEO, President & Director | Lisa A. Conte (age 66) |
|---|---|
| Chief Scientific Officer & Chair of Scientific Advisory Board | Pravin R. Chaturvedi (age 62) |
| Chief Financial Officer | Carol R. Lizak (age 61) |
| Senior Director of Investor Relations, Business Development & Special Events | Peter Hodge |
| President of Jaguar International | Massimo Radaelli (age 67) |
Major Backers & Investors (JAGX)
Notable institutional backers of Jaguar Health, Inc. include UBS Group AG, Fidelity, according to Nexqual as of June 10, 2026 at 02:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| UBS Group AG | 0.53% |
| Fidelity | 0.51% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.52% |
Source: Nexqual, June 10, 2026 at 02:03 UTC.
From Jaguar Health, Inc.'s Latest SEC 10-K Filing (filed 2026-04-07)
Key Strengths & Strategy (as disclosed to the SEC)
- Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress.
- It operates through two segments, Animal Health and Human Health.
- The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
- Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OCGN | Ocugen, Inc. | USD 1.24 | ▼ 3.13% |
| BNGO | Bionano Genomics, Inc. | USD 1.16 | ▼ 0.85% |
| TNXP | Tonix Pharmaceuticals Holding C | USD 11.46 | ▲ 3.52% |
| MBAI | Check-Cap Ltd. | USD 1.4 | ▲ 1.45% |
| CTRM | Castor Maritime Inc. | USD 2.18 | ▲ 2.35% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:03 UTC. This page is informational and not investment advice.